Press release archive | Oxurion — Advancing Science. Enhancing Vision

EN
NL

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Press release archive

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)
9 May 2022
Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022
6 May 2022
Oxurion to Participate in Upcoming Conferences
5 May 2022
Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3 May 2022
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
29 Apr 2022
Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11 Apr 2022
Oxurion Announces Extraordinary and Annual Shareholders’ Meetings
1 Apr 2022
Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA
30 Mar 2022
Oxurion to Participate in Needham Virtual Healthcare Conference
28 Mar 2022
Oxurion Publishes 2021 Annual Report
25 Mar 2022
Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG
17 Mar 2022
Oxurion Successfully Closes EUR >10 Million in Private Placement
7 Mar 2022
Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement
3 Mar 2022
Oxurion NV announces 2021 Full Year Results and 2022 Outlook
22 Feb 2022
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
22 Feb 2022
Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference
14 Feb 2022
Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
11 Feb 2022
Oxurion to Participate in the 2022 BIO CEO and Investor Conference
8 Feb 2022
OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
18 Jan 2022
Oxurion Provides Update on Clinical Pipeline Progress
7 Jan 2022
OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
4 Jan 2022
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
30 Dec 2021
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
30 Nov 2021
OXURION to Present at the Ophthalmology Day at BTIG
24 Nov 2021
OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures
22 Nov 2021
First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)
15 Nov 2021
Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation
4 Nov 2021
Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA
3 Nov 2021
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)
13 Oct 2021
Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Specialists (ASRS) Annual Scientific Meeting
11 Oct 2021
OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
5 Oct 2021
OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
30 Sep 2021
Oxurion NV Business & Financial Update – H1 2021
9 Sep 2021
OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress
8 Sep 2021
Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal
17 Aug 2021
Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149
16 Aug 2021
OXURION to Participate in Upcoming Investor Meetings
5 Aug 2021
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
25 Jun 2021
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
10 Jun 2021
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
8 Jun 2021

Pages